Urinary Tract Infection (UTI) Cell Models for Research

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide. According to WHO, UTIs affect an estimated 150 million people annually, with a higher prevalence in women; approximately 50-60% of women experience at least one UTI in their lifetime. The global incidence is projected to rise due to antimicrobial resistance. Key risk factors include female anatomy, sexual activity, catheter use, diabetes, and immunosuppression. Complicated UTIs can lead to pyelonephritis and sepsis, with mortality rates up to 10% in severe cases. Recurrence is common, with 25-30% of women experiencing recurrent UTIs within 6 months. The economic burden exceeds $3.5 billion annually in the US alone. Unlike cancers, UTI does not have stage-based survival rates; however, the NCI reports that bladder infections are not directly linked to cancer, but chronic inflammation may increase bladder cancer risk. Research models are critical to understand host-pathogen interactions and develop novel therapeutics.

UTI is an ideal model for mechanistic studies due to its well-characterized bacterial pathogens, primarily uropathogenic Escherichia coli (UPEC), and the availability of human bladder epithelial cell lines. Subtypes include uncomplicated cystitis, complicated UTI, and catheter-associated UTI. Public datasets such as GEO and ArrayExpress provide transcriptomic data from patient samples and infected cell lines. Open questions include the molecular basis of recurrence, intracellular bacterial community (IBC) formation, and host genetic susceptibility. Gene-edited cell models enable dissection of host factors, such as pattern recognition receptors and inflammatory pathways, that influence infection outcomes.

UTI pathogenesis is not carcinogenic per se, but involves distinct molecular pathways:

1. Bacterial adhesion and invasion:

• • UPEC expresses type 1 fimbriae that bind mannosylated uroplakin receptors on urothelial cells.
• • P fimbriae bind globoseries glycosphingolipids on renal epithelial cells.

2. Innate immune activation:

• • TLR4 recognizes lipopolysaccharide (LPS), triggering MyD88-dependent and TRIF-dependent signaling.
• • NF-kB and IRF3 activation leads to pro-inflammatory cytokine production (IL-6, IL-8, TNF-alpha).

3. Inflammasome activation:

• • NLRP3 inflammasome assembly activates caspase-1, leading to IL-1beta maturation and pyroptosis.

4. Intracellular bacterial community (IBC) formation:

• • UPEC escapes to the cytoplasm, forms biofilm-like IBCs, and can persist as quiescent intracellular reservoirs (QIRs), causing recurrence.

Host genetic variations influence UTI susceptibility. The table below lists key genes and variants from ClinVar and GWAS studies.

Data from ClinVar and NCBI Gene. Note: Frequencies are approximate and vary by population.

Key signaling networks in UTI pathogenesis:

• • TLR4/MyD88/NF-kB axis:
• • TLR4 activation recruits MyD88, IRAK4, TRAF6, leading to IKK activation and NF-kB nuclear translocation.
• • Drives expression of pro-inflammatory cytokines and antimicrobial peptides.
• • TLR4/TRIF/IRF3 axis:
• • TRIF recruits TBK1 and IKKepsilon, phosphorylating IRF3, which induces type I interferons.
• • Important for viral-like response and bacterial clearance.
• • NLRP3 inflammasome:
• • Activated by K+ efflux, ROS, and lysosomal damage; leads to caspase-1 activation and IL-1beta release.
• • PI3K/AKT/mTOR pathway:
• • Activated by UPEC to promote host cell survival and bacterial internalization.
• • Inhibits apoptosis, facilitating IBC formation.
• • MAPK cascade:
• • ERK, JNK, and p38 are activated, regulating cytokine production and cell survival.
• • Wnt/beta-catenin:
• • Implicated in bladder regeneration and fibrosis post-infection.

Common cell lines for UTI research include:

Organoids derived from bladder epithelium offer advantages: they recapitulate tissue architecture, contain multiple cell types, and can be infected with UPEC to study IBC formation. They are suitable for CRISPR screening and host-pathogen interaction studies.

Animal models for UTI include:

• • Mouse models:
• • C3H/HeJ mice (TLR4 mutant) are susceptible to asymptomatic bacteriuria.
• • C57BL/6 mice are commonly used for induced UTI via intraurethral inoculation.
• • Knockout mice (e.g., TLR4-/-, MyD88-/-, NLRP3-/-) help dissect immune pathways.
• • Rat models:
• • Used for ascending UTI and pyelonephritis studies.
• • Non-human primate models:
• • Rarely used due to ethical and cost considerations.
• • Patient-derived xenografts (PDX):
• • Not applicable for UTI as it is an infection, not cancer.
• • Induced models:
• • Catheter-associated UTI models in mice and rats.
• • Cyclophosphamide-induced immunosuppression to mimic complicated UTI.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TLR4 knockout in 5637 bladder epithelial cells to study LPS hyporesponsiveness.
• • IRF3 knockout in T24 cells to assess type I interferon role in bacterial clearance.
• • NLRP3 knockout in RT4 cells to investigate inflammasome contribution to cystitis.
• • CXCR1 knockout in primary urothelial cells to model impaired neutrophil recruitment.
• • Knock-in of TLR4 D299G variant to mimic human susceptibility.
• • Reporter lines with NF-kB-driven luciferase or GFP for high-throughput screening.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are generated using CRISPR and are quality-controlled for off-target effects and karyotype stability.

Gene-edited cell lines enable functional validation of host factors in UTI. For example:

• • TLR4 knockout cells confirm the receptor's role in LPS sensing and cytokine production.
• • IRF3 knockout cells show reduced interferon-beta and increased bacterial load.
• • NLRP3 knockout cells demonstrate decreased IL-1beta and pyroptosis.
• • CRISPR activation (CRISPRa) screens can identify host restriction factors.
• • CRISPR interference (CRISPRi) screens can uncover genes required for UPEC invasion.

Isogenic pairs (wild-type vs. knockout) are powerful for drug screening:

• • Test candidate antibiotics or anti-virulence compounds for efficacy.
• • Identify host-directed therapies that modulate immune pathways.
• • Model antibiotic resistance by exposing cells to sublethal doses and selecting resistant mutants.
• • Evaluate combination therapies targeting both bacteria and host factors.
• • High-throughput screening with reporter lines (e.g., NF-kB-luciferase) quantifies inflammatory responses.

CRISPR synthetic lethality screens can identify host genes essential for UPEC survival:

• • Genome-wide knockout libraries in bladder cells infected with UPEC reveal vulnerabilities.
• • Candidate biomarkers can be validated in patient cohorts using GEO datasets.
• • Genetic variants (e.g., TLR4 D299G) can be modeled to predict UTI susceptibility.
• • Epigenetic markers (e.g., DNA methylation) can be studied using CRISPR-dCas9 systems.